{"filing":{"accession_number":"0001213900-26-092083","cik":"0001893645","ticker":"PLRZ","company_name":"Polyrizon Ltd.","form":"6-K","filing_date":"2026-08-20","report_date":"2026-08-20","primary_document":"ea0302853-6k_polyrizon.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1893645/000121390026092083/ea0302853-6k_polyrizon.htm"},"events":[{"id":28832,"run_id":26387,"accession_number":"0001213900-26-092083","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces completion of clinical site contracting for Polyrizon's NASARIX™ first-in-human clinical trial and advancement toward patient enrollment. As a development-stage biotech company, this represents a material operational and strategic milestone in advancing its lead product toward commercialization. The disclosure describes concrete progress (all five U.S. clinical sites contracted, 120-patient trial design, primary and secondary endpoints defined) that would affect a reasonable investor's assessment of the company's clinical development trajectory and near-term execution capability.","company_name":"Polyrizon Ltd.","ticker":"PLRZ","filing_date":"2026-08-20","form":"6-K","submitted_at":null,"items":[{"id":30890,"accession_number":"0001213900-26-092083","item_number":"EX-99.1","item_title":"ea030285302ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of clinical site contracting for Polyrizon's NASARIX™ first-in-human clinical trial and advancement toward patient enrollment. As a development-stage biotech company, this represents a material operational and strategic milestone in advancing its lead product toward commercialization. The disclosure describes concrete progress (all five U.S. clinical sites contracted, 120-patient trial design, primary and secondary endpoints defined) that would affect a reasonable investor's assessment of the company's clinical development trajectory and near-term execution capability.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:04:53.414342+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30890,"accession_number":"0001213900-26-092083","item_number":"EX-99.1","item_title":"ea030285302ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of clinical site contracting for Polyrizon's NASARIX™ first-in-human clinical trial and advancement toward patient enrollment. As a development-stage biotech company, this represents a material operational and strategic milestone in advancing its lead product toward commercialization. The disclosure describes concrete progress (all five U.S. clinical sites contracted, 120-patient trial design, primary and secondary endpoints defined) that would affect a reasonable investor's assessment of the company's clinical development trajectory and near-term execution capability.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:04:53.414342+00:00","company_name":"Polyrizon Ltd.","ticker":"PLRZ","filing_date":"2026-08-20"}]}